Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 25, 2026
GLP-3R vs Semaglutide at a Glance
- GLP-3R (retatrutide) is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors, while semaglutide targets only GLP-1, creating different efficacy and tolerability profiles.
- 2026 Phase 3 data show retatrutide 12 mg achieved 28.3% mean weight loss at 80 weeks, outperforming semaglutide 2.4 mg in comparable trials.1
- Gastrointestinal side-effect rates are similar between the two agents, but retatrutide introduces a dose-dependent dysesthesia signal not seen with semaglutide.
- Supervised compounding at Mirror Plastic Surgery includes comprehensive lab review, batch-tested sourcing, and 24/7 clinical support to reduce risks tied to unregulated online peptides.
- Patients considering GLP-3R or semaglutide can book a consultation at Mirror Plastic Surgery to review labs and select the most appropriate protocol.
How GLP-3R Differs From Semaglutide
GLP-3R (retatrutide, LY3437943) is not the same as semaglutide. Semaglutide is selective for the GLP-1 receptor with no meaningful agonist activity at the GIP or glucagon receptors at therapeutic concentrations. Its weight-loss effect comes from reduced caloric intake through central appetite suppression mediated by GLP-1 receptors in the arcuate nucleus of the hypothalamus and brainstem circuits.
Retatrutide simultaneously activates the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR), while semaglutide selectively targets only the GLP-1 receptor and does not engage GIPR or GCGR. GCGR agonism in retatrutide raises whole-body energy expenditure and promotes hepatic fatty acid oxidation via cAMP/PKA signaling and PGC-1alpha upregulation, effects that do not occur with semaglutide.
Triple agonists such as GLP-1/GIP/glucagon agents add thermogenic and lipid-oxidizing effects via glucagon receptor activation, while GLP-1 and GIP signaling help counterbalance glucagon’s hyperglycemic potential. Both agents share once-weekly subcutaneous dosing and albumin-binding half-lives that support that schedule, but their receptor non-redundancy produces distinct metabolic footprints. The table below summarizes the key mechanistic and clinical differences that guide protocol selection.
| Metric | Retatrutide (GLP-3R) | Semaglutide |
|---|---|---|
| Receptor Mechanism | Triple agonist: GLP-1R, GIPR, GCGR | Single agonist: GLP-1R only |
| 2026 Phase 3 Weight Loss (Primary Endpoint) | −28.3% at 80 weeks (12 mg, TRIUMPH-1) | Substantial weight loss at 68 weeks in STEP 1 (2.4 mg) |
| GI Side-Effect Incidence (Nausea) | ~43% at 12 mg (TRIUMPH-4) | ~44% at 2.4 mg (STEP 1) |
| Discontinuation Due to Adverse Events | Observed at highest dose in TRIUMPH-1 | Observed in SELECT trial |
| FDA Approval Status | Investigational; no approval as of mid-2026 | FDA-approved for T2DM and chronic weight management |
Ellie Pranckevicius, FNP-BC, leads all peptide therapy protocols at Mirror Plastic Surgery. Her clinical foundation includes a Bachelor’s in Health Science from Boston University on the premedical track, a Master’s in Nursing from the University of South Florida, and four years in the Neuroscience ICU at Tampa General Hospital managing complex metabolic and neurological cases. Her dual background as a licensed esthetician and board-certified family nurse practitioner gives her a rare command of both the aesthetic outcomes patients seek and the clinical science required to pursue them safely. That combination directly shapes how she structures lab-guided GLP-3R compounding protocols.
Retatrutide as a High-Efficacy GLP-Class Option
Retatrutide 12 mg produced mean weight loss of −28.3% at 80 weeks in the TRIUMPH-1 Phase 3 trial (n=2,339 adults with obesity or overweight plus at least one weight-related comorbidity and no diabetes).1 In a pre-specified TRIUMPH-1 extension for participants with baseline BMI ≥35 who continued retatrutide 12 mg through 104 weeks, mean weight loss reached 30.3% (85.0 lbs).1
By comparison, semaglutide 2.4 mg produced substantial mean weight loss over 68 weeks in STEP 1 and at 104 weeks in STEP 5.1 Analyses of GLP-1 receptor agonists and polyagonists have shown retatrutide 12 mg to produce substantial mean weight loss compared with other agents.
The shift toward multi-receptor agonists responds directly to the limitations of single-hormone GLP-1 treatment, including weight-loss plateaus at approximately 18 months, substantial inter-individual variability, and weight regain of up to two-thirds of lost weight within one year after discontinuation. Retatrutide’s glucagon receptor component is the primary mechanistic driver of its superior efficacy, adding energy expenditure pathways that semaglutide does not engage.
Why Many Patients Stop Ozempic
Discontinuation due to adverse events occurred more frequently with semaglutide 2.4 mg than with placebo in the SELECT trial, primarily due to gastrointestinal causes. Beyond GI tolerability, lean-mass loss and plateau effects often influence decisions to stop treatment.
Semaglutide-induced weight loss consists of approximately 60–75% fat mass and 25–40% lean mass, a ratio consistent with weight loss from any cause including diet or surgery.1 For patients with fitness or body-composition goals, that lean-mass fraction can be a meaningful concern. Real-world data show that semaglutide efficacy is often lower than trial figures in patients with T2DM, suggesting that plateau effects are common outside controlled settings.
At Mirror Plastic Surgery, Ellie addresses these concerns through individualized lab panels that assess thyroid, liver, kidney, diabetes markers, and hormone levels before starting any GLP-class protocol. Dose titration, protein intake guidance, and resistance-training recommendations are built into the protocol from the outset, rather than added only after side effects appear.
Side Effects: GLP-3R Compared With Semaglutide
The GI side-effect incidence of retatrutide and semaglutide is broadly comparable at their respective highest doses. In the TRIUMPH-4 Phase 3 trial of 445 adults with obesity and knee osteoarthritis over 68 weeks, retatrutide 12 mg produced nausea in 43.2% of participants versus 10.7% on placebo, diarrhea in 33.1% versus 13.4%, constipation in 25.0% versus 8.7%, and vomiting in 20.9% versus 0%. Cross-trial comparison shows nausea rates of approximately 43% with retatrutide 12 mg versus 44% with semaglutide 2.4 mg in STEP 1.
Retatrutide carries one side-effect signal not observed with semaglutide: dysesthesia. Dysesthesia emerged as a dose-dependent safety signal in TRIUMPH-4 (8.8% at 9 mg, 20.9% at 12 mg) that was not reported in Phase 2 trials or in prior semaglutide or tirzepatide studies, and events were generally mild to moderate and most resolved during treatment.
Semaglutide carries its own distinct risk profile. Semaglutide carries a boxed warning for risk of thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Cholelithiasis-related events have been reported with semaglutide, with the highest risk during active weight loss.
On lean-mass loss, lean-mass loss accounts for 25–40% of total weight lost on GLP-1 class drugs including retatrutide, and protein intake plus resistance training are the primary recommended mitigations.1 Long-term cardiovascular, renal, and cancer safety data for retatrutide will be provided by the ongoing multi-year TRIUMPH-Outcomes cardiovascular outcomes trial (NCT06383390). Given retatrutide’s investigational status and the side-effect profile documented in Phase 3 trials, the quality and oversight of compounding become critical safety variables.
Supervised GLP-3R Compounding vs Online Peptide Sites
The FDA has issued warning letters to firms marketing unapproved retatrutide products labeled for research use, citing violations of the Federal Food, Drug, and Cosmetic Act. Purchasing peptides from unregulated online sources carries compounding risks such as unknown purity, inaccurate dosing, lack of batch testing, and no clinical oversight to screen for contraindications.
Mirror Plastic Surgery’s supervised GLP-3R compounding protocol addresses each of these risks through a structured concierge framework. The foundation is a 30–60 minute lab-reviewed consultation with Ellie that includes thyroid, liver, kidney, diabetes marker, and hormone panels before protocol initiation, which reduces the contraindication risk inherent in online sourcing. Peptides are sourced exclusively from providers with documented batch testing for purity and accurate dosage, directly addressing unknown-purity and misdosing concerns.
Once the protocol begins, patients receive 24/7 direct text access to Ellie for dose questions, side-effect management, and refill requests, which maintains clinical oversight throughout treatment. The full protocol, including consultation, compounding, and ongoing support, is delivered remotely from St. Petersburg, Florida, to patients across the continental United States, Hawaii, and Alaska, with detailed reconstitution and self-administration instructions that include video demonstrations.
This model contrasts directly with many high-volume telemedicine platforms that may prescribe without reviewing current labs or adjusting protocols based on individual metabolic response.
Choosing Between GLP-3R and Semaglutide
The decision between GLP-3R compounding and semaglutide depends on a patient’s current metabolic status, prior treatment history, and tolerance profile. The framework below reflects the clinical considerations Ellie applies during consultation.
Patients for whom semaglutide may be the appropriate starting point include those with the following characteristics.
- No prior GLP-1 therapy and no documented plateau on a single-receptor agonist, which makes a well-studied first-line option reasonable.
- Preference for an agent with a longer published safety record across multiple large trials, supporting comfort with long-term use.
- Contraindications to glucagon receptor agonism, such as specific hepatic conditions that require individualized assessment.
Patients for whom supervised GLP-3R compounding warrants evaluation often share different features.
- Documented weight-loss plateau on semaglutide or tirzepatide despite adherence, suggesting that a multi-receptor approach may offer additional benefit.
- Metabolic goals that extend beyond weight loss, including insulin resistance, hepatic fat reduction, or cardiovascular risk factor management.
- Higher baseline BMI for whom the superior efficacy demonstrated in TRIUMPH-1 represents a clinically meaningful incremental benefit over semaglutide.
- History of discontinuing semaglutide due to GI intolerance and interest in a protocol with individualized dose titration and ongoing clinical support.
Neither agent is appropriate without baseline lab review. The regulatory status of retatrutide, investigational with no FDA marketing approval as of mid-2026, means that access outside clinical trials occurs through compounding under medical supervision, which makes the quality of that supervision the primary safety variable.
Frequently Asked Questions
Is retatrutide (GLP-3R) available without a prescription or clinical trial enrollment?
Retatrutide has not received FDA marketing approval as of mid-2026 and is not available through standard pharmacy channels. Legitimate access outside of clinical trials occurs only through medically supervised compounding under the oversight of a licensed practitioner who reviews labs, screens for contraindications, and sources from batch-tested suppliers. Purchasing retatrutide from unregulated online retailers carries significant safety risks, including unknown purity and inaccurate dosing, and the FDA has issued warning letters to firms marketing unapproved retatrutide products.
How does Ellie’s consultation process differ from a standard telehealth prescription?
Ellie conducts 30–60 minute consultations that include a full review of medical history, current medications, and lab panels covering thyroid, liver, kidney, diabetes markers, and hormone levels. If labs are not available, she orders them before any protocol begins. This approach contrasts with many high-volume platforms that may issue prescriptions without reviewing current metabolic data. Patients also receive 24/7 direct text access to Ellie throughout their protocol, not a general support line.
What happens to muscle mass on GLP-3R or semaglutide?
Both agents are associated with lean-mass loss as a proportion of total weight lost. Across GLP-1 class drugs including retatrutide, lean-mass loss accounts for approximately 25–40% of total weight reduction. Mirror Plastic Surgery’s protocols address this directly. Ellie integrates protein intake targets and resistance-training guidance into every weight-management protocol from the outset, and lab panels are used to monitor metabolic markers throughout treatment. Sermorelin and Ipamorelin, growth hormone-releasing peptides also offered at Mirror, may be considered as adjuncts to support muscle retention depending on individual lab results and goals.
Can GLP-3R compounding be managed remotely if I am not in Florida?
Yes. Mirror Plastic Surgery delivers the full protocol, including consultation, lab review, compounding prescription, and ongoing support, remotely across the continental United States, Hawaii, and Alaska. Consultations occur via telemedicine, and compounded peptides are shipped directly to the patient. Ellie remains accessible via text throughout the protocol regardless of the patient’s location.
What lab work is required before starting a GLP-class peptide protocol?
For weight management protocols, Ellie reviews panels that typically include thyroid function, liver enzymes, kidney function markers, fasting glucose and HbA1c, and a hormone panel. These results guide dose selection, identify contraindications, and establish a baseline for monitoring response. If a patient does not have recent labs, Mirror Plastic Surgery can order them as part of the consultation process. This lab-first approach is a core differentiator from online sourcing, where no such screening occurs.
Medical Disclaimer: The information in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide (GLP-3R) is an investigational compound that has not received FDA marketing approval as of the date of publication (August 25, 2026). Peptide therapies are not FDA-regulated. All clinical decisions, including the initiation or modification of any peptide protocol, should be made in consultation with a licensed healthcare provider who has reviewed your individual medical history and laboratory results. Clinical trial data cited reflect results in specific study populations and may not predict outcomes for any individual patient.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
